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January 2017 Abstracts S427administration and adverse event management costs
were included in the model. The base-case analysis used
a time horizon of 20 years. Costs and health outcomes
were discounted at a rate of 3% per year.
Results: Base case results project for PD-L1 positive
(TPS>¼50%) patients treated with pembrolizumab a
mean survival of 2.25 years. For docetaxel, a mean sur-
vival time of 1.07 years was estimated. Weekly disease
management costs observed in KN010 for the progres-
sion-free state were $866 and $1,298 for pembrolizumab
and docetaxel, respectively. Weekly disease management
costs for the progressive disease state were $1,938 based
on a US healthcare claim database. Results projected total
diseasemanagement costs to be $166Kper patient treated
with pembrolizumab compared with $93K for docetaxel
because of extended progression-free and post-progres-
sion survival with pembrolizumab. Nearly half (45%) of
total expected cost differences between pembrolizumab
and docetaxel are due to the incremental disease man-
agement costs. Further analyses that exclude drug treat-
ment costs show that the additional disease management
costs associated with extended progression-free and
overall survival exceed $50,000 per LY gained ($61,864).
Conclusion: Pembrolizumab improves outcomes
compared to docetaxel in PD-L1 positive (TPS>¼50%)
pre-treated advanced NSCLC patients in the US. The
improved overall survival with pembrolizumab is
accompanied by the economic reality of additional non-
pembrolizumab costs that represent their own substan-
tial economic burden.
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NIVO ALL COMERS 0.148 129 K 885 0
NIVO PD-L1 > 1% 0.201 108 K 570 315
PEMBRO PD-L1 > 1% 0.138 137 K 666 NA
NIVO ALL SQ/ > 1% NSQ 0.216 99 K 738 147
PEMBRO PD-L1 > 50% 0.164 116 K 285 NAScottsdale/AZ/United States of America, 4HCOR Cancer
Center, São Paulo/Brazil
Background: Delivering high quality cancer care at an
affordable cost is one of the main challenges for health
care professionals and policy makers, especially in low-
and middle-income countries. The objective of our study
is to assess the economic impact of nivolumab and
pembrolizumab with and without the use of PD-L1 as a
biomarker in Brazil.
Methods: We developed a decision-analytic model to
determine the cost-effectiveness of PD-L1 assessment
and the second-line treatment with NIVO or PEMBRO
versus docetaxel. The model used outcomes data from
randomized clinical trials and drug acquisition costs
were estimated using current prices in Brazil. Thereafter,
we used Brazilian epidemiologic data to estimate the
economic impact.
Results: We included three RCTs (two with NIVO and
one with PEMBRO). The estimated number of cases
eligible for therapy with immune checkpoint inhibitors is
4,733. Treating all patients with NIVOLUMAB would cost
US$ 173 million dollars each year, representing an in-
crease of 21% in current Brazilian expenses for cancer
drugs acquisition. Treating only patients with PD-L1 >
1% with NIVOLUMAB would cost 93 million dollars
every year, leading to an increase of 11.3% in expenses
for cancer drugs acquisition. However, with such selec-
tion, up to 46% of cases would not be treated and 315
years of life would be lost compared to treating all pa-
tients regardless of PD-L1 expression. The cost of each
year-of-life saved was improved by PD-L1 selection
(from US$ 196,000 to US$ 164,000). Table 1 summarizes
our findings for five different scenarios of treatment. The
results were similar with NIVOLUMAB and
PEMBROLIZUMAB.
Conclusion: The use of PD-L1 expression as a biomarker
for treatment with immune checkpoint inhibitors de-
creases the overall economic impact and the cost per
life-year saved. Further study and societal discussion is
needed in order to find the optimal strategy for patient
selection.
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46% 93 11.3% 164 K
34% 100 12.1% 150 K
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